Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that it set July 29, 2025, as the record date to determine shareholders entitled to exercise voting rights at the upcoming Extraordinary General Meeting of Shareholders. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Record…

Read More “[Disclosure] Samsung Biologics (207940) – Setting of Record Date or Period for Closure of Shareholder Register / 2025-07-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted a corrected disclosure after receiving the official 1st instance court judgment regarding the COVID-19 diagnostic kit lawsuit with Humasis, detailing the specific order and noting a separate favorable ruling of approx. KRW 3.89B in Celltrion’s counter-suit. 📊 [Key Disclosure Details & Financial Summary] 📝…

Read More “[Disclosure] Celltrion (068270) – Rulings on Lawsuit (Correction) / 2025-07-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice disclosing that it plans to announce its Q2 2025 financial results (covering Jan 1, 2025 – Jun 30, 2025) on July 23, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Earnings…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Financial Results Announcement / 2025-07-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion was ordered in a first-instance ruling to pay approx. KRW 12.71B in a lawsuit filed by Humasis regarding COVID-19 diagnostic kit supply contracts, and plans to file an appeal. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] Celltrion (068270) – Rulings on Lawsuit (Claims Exceeding Specific Amount) / 2025-07-03” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received Phase 3 Clinical Trial Application (IND) approval from the Ministry of Food and Drug Safety (MFDS) of Korea for ‘CT-P44’, a biosimilar candidate to Darzalex, enabling patient recruitment and clinical trial execution in South Korea. 📊 [Key Disclosure Details & Financial Summary] 📝…

Read More “[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan in Korea for CT-P44 (Darzalex Biosimilar) / 2025-07-03” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire 623,053 common treasury shares (valued at approx. KRW 100.0B) through open market purchases to stabilize share prices and enhance shareholder value, with plans to fully cancel all acquired shares. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Treasury Shares / 2025-06-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted Part 2 (site and execution assessment) of its Phase 3 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for ‘CT-P44’, a biosimilar candidate to Darzalex. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] Celltrion (068270) – Submission of Phase 3 Clinical Trial Plan (Part 2) in Europe for CT-P44 (Darzalex Biosimilar) / 2025-06-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed the signing of a pharmaceutical contract manufacturing agreement with a European pharmaceutical company valued at approx. KRW 102.5B (USD 75,392,300). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Contract Execution and Subsequent Official Disclosures…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract (Voluntary Disclosure) / 2025-06-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange (KRX) announced an ex-rights reference price of KRW 157,100 per common share for Celltrion following its bonus issue decision, effective on the ex-rights date of June 9, 2025. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – Notice of Ex-Rights Reference Price / 2025-06-05” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange (KRX) announced market adjustments for Celltrion stock futures and options—including base prices, contract multipliers, and strike prices—effective June 9, 2025, in response to Celltrion’s bonus issue. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Derivatives…

Read More “[Disclosure] Celltrion (068270) – Market Measures Notice on Stock Futures and Options (Bonus Issue Adjustments) / 2025-06-05” »